KCM
PAND

Kathmere Capital Management’s Pandion Therapeutics Inc. Common Stock PAND Stock Holding History

Kathmere Capital Management’s Portfolio PAND Stock Details PAND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-160
Closed -$2K – 430
2020
Q4 		$2K Buy
+160
New +$2.23K ﹤0.01% 392

Other funds holding PAND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
VI
Versor Investments New York $47.5M AUM 100.43% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Kathmere Capital Management's PAND Position: Q1 2021 in Review

Kathmere Capital Management sold out of Pandion Therapeutics Inc. Common Stock (PAND) in Q1 2021, closing a stake of 160 shares — an estimated $2K sold.

Kathmere Capital Management first reported a position in PAND in Q4 2020 and held it in 1 quarter. The position peaked at $2K in Q4 2020. 75 funds tracked by Wall St. Rank hold PAND as of Q1 2021.

  • Kathmere Capital Management reported no remaining Pandion Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Kathmere Capital Management sold 160 Pandion Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $2K.
  • Kathmere Capital Management first reported a position in Pandion Therapeutics Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • Kathmere Capital Management's Pandion Therapeutics Inc. Common Stock position peaked at $2K in Q4 2020.
  • 75 funds tracked by Wall St. Rank held Pandion Therapeutics Inc. Common Stock as of Q1 2021.

Based on Kathmere Capital Management's 13F filing for Q1 2021, filed 7 May 2021.